secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001193125-26-183563
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Q1 revenue $38.2M; net loss narrows to $26.1M; WVE-007 Phase 2a begins Q2 2026
--------------------------------------------------------------------------------

- Revenue $38.2M (up from $9.2M); net loss $26.1M (vs $46.9M).
- Cash $544.6M; runway into Q3 2028, excluding GSK milestones.
- FDA accepted Phase 2a multidose portion of WVE-007 (obesity); trial to start Q2 2026.
- Phase 1 six-month data: total fat -5.3%, visceral fat -14.3% (p<0.05), muscle +2.4%.
- WVE-006 AATD data at ATS May 18 & EASL May 29; accelerated approval feedback mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526183563/0001193125-26-183563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312526183563/d135689d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-183563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer